<p>在过去的 7 天里，市场上涨了 3.4%，在过去一年中更是令人印象深刻地上涨了 30%，预计年收益将增长 16%。在如此强劲的市场条件下，识别财务状况良好的股票对于希望抓住增长机会的投资者来说变得至关重要。尽管通常被视为过时的选择，低价股在坚实的基本面支持下仍然具有潜力，提供了一种在大型公司中可能找不到的独特价值与增长的结合。</p>
<h3>美国十大低价股</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>回报与风险</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.4011</td>
<td>$69.45M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.19</td>
<td>$375.23M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.97</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7079</td>
<td>$81.81M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.48</td>
<td>$369.14M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.14</td>
<td>$897.95M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.02</td>
<td>$52.12M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国低价股筛选器中的 361 只股票的完整列表。</p>
<p>让我们深入探讨筛选器中的一些优质选择。</p>
<h2>Ceragon Networks (CRNT)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Ceragon Networks Ltd. 为全球各地的蜂窝运营商和其他无线服务提供商提供无线传输解决方案，市值约为 2.0675 亿美元。</p>
<p><strong>运营：</strong> 该公司作为全球创新者和领先的无线传输解决方案提供商，产生了 3.3873 亿美元的收入。</p>
<p><strong>市值：</strong> $206.75M</p>
<p>Ceragon Networks Ltd. 正在应对无盈利的挑战，2025 年最近的净亏损为 209 万美元，尽管它保持着强劲的现金状况，短期资产超过其短期和长期负债。尽管目前缺乏盈利能力，该公司预计 2026 年的收入将显著增长，介于 3.55 亿至 3.85 亿美元之间，并预计年收益将增长 90.75%。Ceragon 的管理团队经验丰富，平均任期为 4.9 年，表明在财务波动和行业竞争中领导层的稳定性。</p>
<ul>
<li>在我们的财务健康报告中更详细地了解 Ceragon Networks 的潜力。</li>
<li>通过访问我们的收益增长报告评估 Ceragon Networks 的前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/08f68317-5a21-4cf0-8836-1cd929c959c7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/08f68317-5a21-4cf0-8836-1cd929c959c7/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 CRNT 的债务与股本历史及分析</p>
<h2>Caesarstone (CSTE)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Caesarstone Ltd. 设计、开发、制造和销售各种品牌的工程石和瓷器产品，覆盖美国、加拿大、拉丁美洲、澳大利亚、亚洲、欧洲、中东和非洲以及以色列，市值为 4702 万美元。</p>
<p><strong>运营：</strong> 该公司从其建筑产品部门产生了 3.9723 亿美元的收入。</p>
<p><strong>市值：</strong> $47.02M</p>
<p>Caesarstone Ltd. 面临财务挑战，2025 年净亏损为 1.3747 亿美元，收入从 4.4322 亿美元下降至 3.9723 亿美元，反映出其无盈利状态。尽管如此，该公司保持着强劲的现金状况，短期资产为 2.531 亿美元，超过短期负债 1.382 亿美元和长期负债 1.211 亿美元，表明短期内的财务稳定性。债务与股本比率在五年内从 7.3% 改善至 2.2%，但增加的波动性和有限的现金流仍然是潜在投资者在低价股中的担忧。</p>
<ul>
<li>点击探索我们在 Caesarstone 财务健康报告中的详细发现。</li>
<li>在我们的历史业绩报告中探索 Caesarstone 的表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 CSTE 的债务与股本历史及分析</p>
<h2>Protalix BioTherapeutics (PLX)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Protalix BioTherapeutics, Inc. 是一家生物制药公司，专注于开发、生产和商业化重组治疗蛋白，使用其 ProCellEx 植物细胞基础的蛋白表达系统，市值为 1.8129 亿美元。</p>
<p><strong>运营：</strong> 该公司从其生物技术（初创企业）部门产生了 5274 万美元的收入。</p>
<p><strong>市值：</strong> $181.29M</p>
<p>Protalix BioTherapeutics, Inc. 最近获得了欧洲委员会对 pegunigalsidase alfa 新剂量方案的批准，可能增强其在 Fabry 病治疗中的市场地位。该批准使 Protalix 有资格获得来自 Chiesi Global Rare Diseases 的 2500 万美元的监管里程碑付款。尽管 2025 年报告净亏损 660 万美元，该公司预计 2026 年收入将增加，介于 7800 万至 8300 万美元之间，得益于预期的销售增长和里程碑付款。Protalix 保持无债务，短期资产超过负债，表明在其无盈利状态下的财务稳定性。</p>
<ul>
<li>在我们的详细资产负债表健康报告中深入了解 Protalix BioTherapeutics 的具体情况。</li>
<li>在我们的增长报告中探索 Protalix BioTherapeutics 的分析师预测。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/65ba3298-13c3-4cf9-b3e1-38fa2f9a1459/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/65ba3298-13c3-4cf9-b3e1-38fa2f9a1459/chart/financial-position-analysis"/></p>
<p>截至 2026 年 4 月的 PLX 财务状况分析</p>
<h2>下一步</h2>
<ul>
<li>点击这里，一键揭示我们美国便士股票筛选器中的 361 个隐藏宝石。</li>
<li>对其他可能性感兴趣？今天最好的人工智能股票可能不在像 Nvidia 和 Microsoft 这样的巨头之中。通过这些 20 家专注于人工智能的小型公司，寻找下一个重大机会，这些公司在机器学习、自动化和数据智能方面的早期创新具有强大的增长潜力，可能为您的退休提供资金。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新：</strong> 人工智能股票筛选器与警报</h3>
<p>我们的新人工智能股票筛选器每天扫描市场以发现机会。</p>
<p>• 分红强劲的公司（收益率 3% 以上）</p>
<p>• 内部人士购买的被低估小型股</p>
<p>• 高增长的科技和人工智能公司</p>
<p>或者从 50 多个指标中构建您自己的筛选器。</p>
<p>立即免费探索</p>

Ceragon网络

MAPS

Protalix生物治疗

乐信集团

<p>市场在过去一周上涨了 3.4%，在过去一年中上涨了 30%，预计年收益将增长 16%。常常被忽视的低价股可以提供独特的价值和增长机会。值得注意的低价股包括 WM Tech、乐信集团和 Ceragon Networks，尽管面临一些财务挑战，但显示出显著的收入增长潜力。Ceragon 预计年收入增长将达到 90.75%，而 Protalix 生物治疗已获得 2500 万美元的里程碑付款，尽管目前亏损，但显示出强劲的前景。投资者被鼓励探索低价股市场中的这些机会</p>

<p>The market has climbed 3.4% in the last 7 days and an impressive 30% over the past year, with earnings projected to grow annually by 16%. In light of these robust market conditions, identifying stocks with strong financials becomes crucial for investors looking to capitalize on growth opportunities. Although often considered a relic, penny stocks still hold potential when backed by solid fundamentals, offering a unique blend of value and growth that might not be found in larger companies.</p>
<div class="lb-trans"><p>在过去的 7 天里，市场上涨了 3.4%，在过去一年中更是令人印象深刻地上涨了 30%，预计年收益将增长 16%。在如此强劲的市场条件下，识别财务状况良好的股票对于希望抓住增长机会的投资者来说变得至关重要。尽管通常被视为过时的选择，低价股在坚实的基本面支持下仍然具有潜力，提供了一种在大型公司中可能找不到的独特价值与增长的结合。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大低价股</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.4011</td>
<td>$69.45M</td>
<td>✅ 3 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.19</td>
<td>$375.23M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.97</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7079</td>
<td>$81.81M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.48</td>
<td>$369.14M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.14</td>
<td>$897.95M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.02</td>
<td>$52.12M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>回报与风险</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.4011</td>
<td>$69.45M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.19</td>
<td>$375.23M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>FinVolution Group (FINV)</td>
<td>$4.97</td>
<td>$1.31B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7079</td>
<td>$81.81M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.48</td>
<td>$369.14M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.14</td>
<td>$897.95M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.02</td>
<td>$52.12M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 361 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国低价股筛选器中的 361 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>让我们深入探讨筛选器中的一些优质选择。</p>
</div><h2>Ceragon Networks (CRNT)</h2>
<div class="lb-trans"><h2>Ceragon Networks (CRNT)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Ceragon Networks Ltd. offers wireless transport solutions for cellular operators and other wireless service providers across various global regions, with a market cap of approximately $206.75 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Ceragon Networks Ltd. 为全球各地的蜂窝运营商和其他无线服务提供商提供无线传输解决方案，市值约为 2.0675 亿美元。</p>
</div><p><strong>Operations:</strong> The company generated $338.73 million in revenue from its role as a global innovator and leading solutions provider of wireless transport.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司作为全球创新者和领先的无线传输解决方案提供商，产生了 3.3873 亿美元的收入。</p>
</div><p><strong>Market Cap:</strong> $206.75M</p>
<div class="lb-trans"><p><strong>市值：</strong> $206.75M</p>
</div><p>Ceragon Networks Ltd. is navigating the challenges of being unprofitable, with a recent net loss of US$2.09 million for 2025, though it maintains a strong cash position with short-term assets exceeding both its short and long-term liabilities. Despite the current lack of profitability, the company forecasts significant revenue growth for 2026 between US$355 million and US$385 million and expects earnings to grow by 90.75% annually. Ceragon's management team is seasoned, with an average tenure of 4.9 years, suggesting stability in leadership amidst financial volatility and industry competition.</p>
<div class="lb-trans"><p>Ceragon Networks Ltd. 正在应对无盈利的挑战，2025 年最近的净亏损为 209 万美元，尽管它保持着强劲的现金状况，短期资产超过其短期和长期负债。尽管目前缺乏盈利能力，该公司预计 2026 年的收入将显著增长，介于 3.55 亿至 3.85 亿美元之间，并预计年收益将增长 90.75%。Ceragon 的管理团队经验丰富，平均任期为 4.9 年，表明在财务波动和行业竞争中领导层的稳定性。</p>
</div><ul>
<li>Take a closer look at Ceragon Networks' potential here in our financial health report.</li>
<li>Evaluate Ceragon Networks' prospects by accessing our earnings growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的财务健康报告中更详细地了解 Ceragon Networks 的潜力。</li>
<li>通过访问我们的收益增长报告评估 Ceragon Networks 的前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/08f68317-5a21-4cf0-8836-1cd929c959c7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/08f68317-5a21-4cf0-8836-1cd929c959c7/chart/debt-equity-history-analysis"/></p>
<p>CRNT Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 CRNT 的债务与股本历史及分析</p>
</div><h2>Caesarstone (CSTE)</h2>
<div class="lb-trans"><h2>Caesarstone (CSTE)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Caesarstone Ltd. designs, develops, manufactures, and sells engineered stone and porcelain products under various brands across multiple regions including the United States, Canada, Latin America, Australia, Asia, Europe, the Middle East and Africa, and Israel with a market cap of $47.02 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Caesarstone Ltd. 设计、开发、制造和销售各种品牌的工程石和瓷器产品，覆盖美国、加拿大、拉丁美洲、澳大利亚、亚洲、欧洲、中东和非洲以及以色列，市值为 4702 万美元。</p>
</div><p><strong>Operations:</strong> The company generates $397.23 million in revenue from its building products segment.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其建筑产品部门产生了 3.9723 亿美元的收入。</p>
</div><p><strong>Market Cap:</strong> $47.02M</p>
<div class="lb-trans"><p><strong>市值：</strong> $47.02M</p>
</div><p>Caesarstone Ltd. faces financial challenges, with a net loss of US$137.47 million for 2025 and declining revenues from US$443.22 million to US$397.23 million year-over-year, reflecting its unprofitable status. Despite this, the company maintains a strong cash position with short-term assets of US$253.1 million exceeding both short-term liabilities of US$138.2 million and long-term liabilities of US$121.1 million, indicating financial stability in the short term. The debt to equity ratio has improved over five years from 7.3% to 2.2%, but increased volatility and limited cash runway remain concerns for potential investors in penny stocks.</p>
<div class="lb-trans"><p>Caesarstone Ltd. 面临财务挑战，2025 年净亏损为 1.3747 亿美元，收入从 4.4322 亿美元下降至 3.9723 亿美元，反映出其无盈利状态。尽管如此，该公司保持着强劲的现金状况，短期资产为 2.531 亿美元，超过短期负债 1.382 亿美元和长期负债 1.211 亿美元，表明短期内的财务稳定性。债务与股本比率在五年内从 7.3% 改善至 2.2%，但增加的波动性和有限的现金流仍然是潜在投资者在低价股中的担忧。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Caesarstone's financial health report.</li>
<li>Explore historical data to track Caesarstone's performance over time in our past results report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在 Caesarstone 财务健康报告中的详细发现。</li>
<li>在我们的历史业绩报告中探索 Caesarstone 的表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/240901f4-ee73-418f-9d8d-4ecf64ca43f7/chart/debt-equity-history-analysis"/></p>
<p>CSTE Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 CSTE 的债务与股本历史及分析</p>
</div><h2>Protalix BioTherapeutics (PLX)</h2>
<div class="lb-trans"><h2>Protalix BioTherapeutics (PLX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based protein expression system, with a market cap of $181.29 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Protalix BioTherapeutics, Inc. 是一家生物制药公司，专注于开发、生产和商业化重组治疗蛋白，使用其 ProCellEx 植物细胞基础的蛋白表达系统，市值为 1.8129 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its Biotechnology (Startups) segment, amounting to $52.74 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司从其生物技术（初创企业）部门产生了 5274 万美元的收入。</p>
</div><p><strong>Market Cap:</strong> $181.29M</p>
<div class="lb-trans"><p><strong>市值：</strong> $181.29M</p>
</div><p>Protalix BioTherapeutics, Inc. has recently secured European Commission approval for a new dosing regimen of pegunigalsidase alfa, potentially enhancing its market position in the treatment of Fabry disease. The approval entitles Protalix to a significant US$25 million regulatory milestone payment from Chiesi Global Rare Diseases. Despite reporting a net loss of US$6.6 million for 2025, the company forecasts increased revenues between US$78 million and US$83 million in 2026, buoyed by expected sales growth and milestone payments. Protalix remains debt-free with short-term assets exceeding liabilities, suggesting financial stability amid its unprofitable status.</p>
<div class="lb-trans"><p>Protalix BioTherapeutics, Inc. 最近获得了欧洲委员会对 pegunigalsidase alfa 新剂量方案的批准，可能增强其在 Fabry 病治疗中的市场地位。该批准使 Protalix 有资格获得来自 Chiesi Global Rare Diseases 的 2500 万美元的监管里程碑付款。尽管 2025 年报告净亏损 660 万美元，该公司预计 2026 年收入将增加，介于 7800 万至 8300 万美元之间，得益于预期的销售增长和里程碑付款。Protalix 保持无债务，短期资产超过负债，表明在其无盈利状态下的财务稳定性。</p>
</div><ul>
<li>Dive into the specifics of Protalix BioTherapeutics here with our thorough balance sheet health report.</li>
<li>Explore Protalix BioTherapeutics' analyst forecasts in our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的详细资产负债表健康报告中深入了解 Protalix BioTherapeutics 的具体情况。</li>
<li>在我们的增长报告中探索 Protalix BioTherapeutics 的分析师预测。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/65ba3298-13c3-4cf9-b3e1-38fa2f9a1459/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/65ba3298-13c3-4cf9-b3e1-38fa2f9a1459/chart/financial-position-analysis"/></p>
<p>PLX Financial Position Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 PLX 财务状况分析</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><ul>
<li>Reveal the 361 hidden gems among our US Penny Stocks screener with a single click here.</li>
<li>Interested In Other Possibilities? The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里，一键揭示我们美国便士股票筛选器中的 361 个隐藏宝石。</li>
<li>对其他可能性感兴趣？今天最好的人工智能股票可能不在像 Nvidia 和 Microsoft 这样的巨头之中。通过这些 20 家专注于人工智能的小型公司，寻找下一个重大机会，这些公司在机器学习、自动化和数据智能方面的早期创新具有强大的增长潜力，可能为您的退休提供资金。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> AI Stock Screener &amp; Alerts</h3>
<div class="lb-trans"><h3><strong>新：</strong> 人工智能股票筛选器与警报</h3>
</div><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p>
<div class="lb-trans"><p>我们的新人工智能股票筛选器每天扫描市场以发现机会。</p>
</div><p>• Dividend Powerhouses (3%+ Yield)</p>
<div class="lb-trans"><p>• 分红强劲的公司（收益率 3% 以上）</p>
</div><p>• Undervalued Small Caps with Insider Buying</p>
<div class="lb-trans"><p>• 内部人士购买的被低估小型股</p>
</div><p>• High growth Tech and AI Companies</p>
<div class="lb-trans"><p>• 高增长的科技和人工智能公司</p>
</div><p>Or build your own from over 50 metrics.</p>
<div class="lb-trans"><p>或者从 50 多个指标中构建您自己的筛选器。</p>
</div><p>Explore Now for Free</p>
<div class="lb-trans"><p>立即免费探索</p>
</div>

2026 年 4 月有潜力的便士股